Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 5, 2009 BioSante Pharmaceuticals, Inc. To Present At BIO CEO and Investor Conference and ISSWSH Conference
LINCOLNSHIRE, Ill.--([ BUSINESS WIRE ])--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), will present at the eleventh annual BIO CEO and Investor Conference and at the 2009 annual International Society for the Study of Women's Sexual Health (ISSWSH) Conference.
Stephen M. Simes, BioSante's president & CEO, will present at the BIO CEO Conference on Monday February 9, 2009 at 1:45 pm EST. Mr. Simes will discuss the LibiGel® (testosterone gel) clinical development plan and primary research data indicating the potential multi-billion dollar size of the U.S. market for BioSante's LibiGel in the treatment of female sexual dysfunction. A live audio webcast of the BIO presentation may be accessed at [ www.biosantepharma.com/Webcasts.php ] and a replay will be available at the same link.
Michael C. Snabes, MD, PhD, BioSante's vice president of clinical development, and Mr. Simes will present on Friday February 13, 2009 at the ISSWSH Conference details about the LibiGel clinical development program and details about current prescribing practices of physicians who treat Hypoactive Sexual Desire Disorder (HSDD) and the need for an FDA approved pharmaceutical product for the treatment of HSDD in the U.S.
The BIO CEO and Investor Conference is the largest investor conference focused on publicly traded biotech companies. The conference features over one hundred companies presenting to investors as well as opportunities for one on one meetings and workshops on issues facing the biotech sector. The ISSWSH annual conference brings together doctors, researchers, investors and companies in a meeting dealing with all issues related to women's sexual health including HSDD.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II/III clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: [ www.biosantepharma.com ].
